Adults eligible for COVID

About 116 million doses of COVID-19 vaccine have been administered in the U.S., according to data published last week by the Centers for Disease Control and Prevention.

All Missouri adults will become eligible for the COVID-19 vaccine by April 9, and all those 16 and older in Illinois become eligible on April 12. Yet, many still have questions — such as how the vaccines work against coronavirus variants and which vaccine is the best to receive.

“Whatever vaccine is available to you the earliest is the best one for you,” said Dr. Dan Hoft, an infectious disease physician, “because they all are shown to be safe, they all work, and the earlier we get people vaccinated, the earlier we can get back to normal life.”

Hoft is the director of St. Louis University’s Center for Vaccine Development. He joined Tuesday’s St. Louis on the Air to discuss the latest vaccine news and answer listener questions, such as why one vaccine would lead to a stronger bodily reaction than others and why some people experience an arm rash after receiving the vaccine.

SLU’s Center for Vaccine Development was involved in developing and testing the Moderna and Johnson & Johnson vaccines currently in use. Now, the center is starting a clinical trial that aims to develop a second-generation vaccine that will be effective against coronavirus variants.

Hoft said the project involves working on combining aspects of current vaccines — like Johnson & Johnson’s antivirus vaccine and Moderna’s self-amplifying mRNA vaccine — to produce two separate immune responses to the coronavirus.

“This trial is not only trying to reduce neutralizing antibodies, which are key, but it's also trying to induce a much better T-cell response, which is the other part of the immune response that can protect us by not making antibodies, but by recognizing an infected cell and eliminating that infected cell before it makes new viral particles,” Hoft said. “That is like a one-two punch, you got two immune responses for one, and that might work better.”

Those interested in enrolling in the trial, or learning more, can visit http://vaccine.slu.edu or call 314-977-6333.

 

You must be logged in to react.
Click any reaction to login.
0
0
0
0
0

(0) comments

Welcome to the discussion.

Keep it Clean. Please avoid obscene, vulgar, lewd, racist or sexually-oriented language.
PLEASE TURN OFF YOUR CAPS LOCK.
Don't Threaten. Threats of harming another person will not be tolerated.
Be Truthful. Don't knowingly lie about anyone or anything.
Be Nice. No racism, sexism or any sort of -ism that is degrading to another person.
Be Proactive. Use the 'Report' link on each comment to let us know of abusive posts.
Share with Us. We'd love to hear eyewitness accounts, the history behind an article.